Question 1

Is NAD+ like Ozempic?

Accepted Answer

No, and the difference is one of kind rather than strength. Ozempic is a brand of semaglutide, a prescription medicine built to copy a gut hormone, and what it was tested for is documented on the Semaglutide overview. NAD+ is a different sort of molecule, which a 2025 review calls a core coenzyme involved in cellular energy metabolism and redox homeostasis, a coenzyme being a helper that enzymes need in order to work. A 2022 Parkinson's paper puts the contrast in its own title, describing NAD+ as A Potential Disease-Modifying Agent Targeting Multiple Pathways. A molecule said to touch many pathways and a medicine designed around one hormone signal are different questions to study, and they produce different kinds of evidence. The question usually behind the comparison is weight, and the outcomes measured in this material were memory, movement, gut bacteria, heart rate and fatigue rather than body weight. So NAD+ is not a cheaper or gentler version of Ozempic in any sense these sources support; it is a separate subject with a much thinner record.

Question 2

Can NAD+ be taken alongside semaglutide or Ozempic?

Accepted Answer

Nothing among the research behind this page gave NAD+ or a precursor to anyone already using semaglutide, Ozempic or retatrutide, so the pairing has no record in either direction. The one combination that was tested in people is useful mainly as a warning about how combinations are read. In that 2016 trial the 80 patients were assigned to receive either CoQ10 plus NADH supplementation or matching placebo twice daily, so the active arm was a pair from the first dose. There was no NADH-only arm and no CoQ10-only arm, which means any effect belongs to the pair. A person adding NAD+ to a GLP-1 medicine is running the same kind of uncontrolled pairing, with no comparison arm at all. What semaglutide does on its own is set out at the Semaglutide safety page. Placing that record next to the NAD+ record does not tell anybody what the two do together, because nobody among these sources measured the combination.

Question 3

Should I get NAD or glutathione?

Accepted Answer

That is a decision these sources cannot make for anyone, because no study among the research behind this page set the two against each other. What they share is a reputation for the same territory, which is why they are offered side by side as drips. Glutathione's own record, by mouth and by vein, is kept on the Glutathione overview. For NAD+, the 2025 heart failure review says NAD+ has been shown to regulate mitochondrial biosynthesis and antioxidant defences, in work the review gathers rather than runs itself. The same review lists excessive accumulation of reactive oxygen species (ROS) leading to oxidative stress injury among the four core faults it examines in failing heart cells. Antioxidant defence is therefore one part of the NAD+ story rather than its whole, and the review's subject is a failing heart rather than general wellbeing. Two compounds that touch the same process are not interchangeable, and a shared word on a clinic menu is not a comparison of outcomes.

Question 4

What is the difference between NAD and Glow?

Accepted Answer

They are different classes of molecule sold for overlapping hopes. GLOW (GHK-Cu + BPC-157 + TB-500) is a blend of three peptides marketed around skin and tissue repair, and its record is set out on the GLOW blend overview. NAD+ is not a peptide at all, and its record points somewhere else entirely. The NAD+ work that reported a positive animal result was about the brain, where the cuprizone + NAD+ group spent a larger share of time in the target quadrant of a water maze than untreated cuprizone mice (28.78% vs. 16.32%, p = 0.023). The other positive mouse result was about the gut, where the paper concluded that the effect of NR on gut dysbiosis may be an important component in its therapeutic functions in AD, dysbiosis meaning a disturbed mix of gut bacteria. Neither touches skin, wounds or tendons. The two records answer different questions, so setting them side by side shows what each was studied for rather than which one does more.

Question 5

Should you take SS-31 before NAD?

Accepted Answer

No study among the research behind this page gave SS-31 and NAD+ in any order, so there is no sequence to report and no evidence that order matters. The pairing comes up because both are discussed in terms of mitochondria, the parts of a cell that turn fuel into usable energy. SS-31, also called elamipretide, has its own record on the SS-31 overview. On the NAD+ side, the 2025 review describes it acting to increase mitochondrial autophagy to remove damaged mitochondria, autophagy being the cell's routine for breaking down worn parts. The review presents that account as groundwork, calling itself a theoretical basis for understanding the central role of NAD+ in mitochondrial homeostasis. Two compounds aimed at the same organelle by different routes could add together, cancel out or do nothing extra, and only an experiment with separate and combined arms could tell those apart. A suggested order of use is therefore a guess about mechanism rather than a finding.

Question 6

What has NAD+ actually been compared against?

Accepted Answer

Against nothing but a blank, which is the honest baseline for every comparison question on this page. In people, the comparison was a matching placebo taken twice daily alongside the active pair. In the anaesthesia experiment the mice in the other arm got vehicle (0.9% normal saline), which is a salt-water shot with nothing else in it. In the cuprizone experiment, the animals not receiving NAD+ were administered saline simultaneously, so the yardstick was again an empty injection. The Alzheimer's model work compared its mice with healthy animals, reporting that compared with wild type (WT) mice, the gut microbiota diversity in AD mice was lower. A placebo or saline comparison asks whether a molecule does anything at all. It does not ask whether it does more than an alternative, which is a different question and the one readers are usually asking.

Question 7

How does the evidence for NAD+ compare with NMN, NADH and NR?

Accepted Answer

Each form has a small record of its own, and the records do not point the same way. NAD+ itself has the one positive brain experiment in mice. NADH has a negative mouse experiment and a share of the one human trial. Nicotinamide mononucleotide has a negative delirium experiment, where the precursor did not rescue the delirium-like sickness behavior and metabolic dysfunction in mice, even though some immune readings shifted. Nicotinamide riboside has the gut bacteria result in Alzheimer's model mice and the most activity on the public register. One registered NR study, Effects of NR Supplementation on Metabolic Flexibility in Zone 2 Training, is still marked RECRUITING. Another, NR Supplementation and Exercise, is marked COMPLETED without a result among these sources. Four forms, a handful of experiments each, and no experiment among these sources that gave two of them side by side. A positive result for one form is not evidence for the others, and a negative one does not count against them either.

Question 8

Has NAD+ been tested head to head with anything?

Accepted Answer

Not among the research behind this page, and the nearest thing is a review that describes two strategies without testing one against the other. The 2025 review notes that the inhibition of NAD+-degrading enzymes increases the tissue intracellular NAD+ content, which is the route of slowing breakdown. It sets that beside the route of adding raw material, where supplementation with NAD+ precursors (e.g., β-nicotinamide mononucleotide (NMN), nicotinamide riboside, etc.) also significantly elevates myocardial NAD+ levels. Myocardial means heart muscle, and the word also in that sentence is doing the work: both routes are reported to raise the level, and neither is ranked. A review listing two approaches side by side does not establish which is stronger, safer or cheaper, and none of the experiments it draws on is described in its summary.

Question 9

Can NAD+ be combined with other compounds?

Accepted Answer

People combine it often, and the registered studies show that researchers do too, which is exactly what makes the results hard to read. One completed entry is filed as Health Benefits of Nutraceutical Supplementation in Older Adults, under PHASE4. Another, Eat2beNICE Vitamins and Nutrients as Supplementation for Impulsivity, Irritability, and Compulsivity, is a mixture of nutrients with its status recorded as UNKNOWN. The human trial that did report was itself a combination of NADH with coenzyme Q10. A design that could separate the parts needs four arms: each compound alone, both together, and placebo. None of the human studies among these sources is described that way, so a combined result can be credited to the mixture rather than to NAD+.

Question 10

Is an NAD+ drip better than a capsule?

Accepted Answer

No study among the research behind this page compared the two, and no study among them gave NAD+ to a person by either route with the route stated. The only routes stated anywhere are injections into the belly cavity of mice, a laboratory method rather than a clinical one. The anaesthesia authors write that the broad implications of NAD+ in aging are likely to shape supplementation trends, which is an observation about demand rather than a measurement of any route. The registered study closest to the shop shelf is Effectiveness of Qualia NAD+ Supplementation on Intracellular NAD Levels, which tests one oral brand against a reading inside cells and carries a status of UNKNOWN. A comparison of routes would need the same person, or matched groups, given each form and measured the same way. Until that exists, a claim that one route works better rests on impression rather than on anything measured.

Question 11

Is NAD+ the same as NADH?

Accepted Answer

They are two states of the same molecule, and the literature does not always keep them apart, which is the confusion most worth knowing about. The anaesthesia paper describes NADH as a common NAD+ precursor in its own summary, while the drips and bottles in shops are usually labelled NAD+. The one human trial uses both names, with a title that reads Effect of coenzyme Q10 plus nicotinamide adenine dinucleotide supplementation on maximum heart rate, while the methods name the compound as NADH. Someone reading that title would reasonably believe the trial gave NAD+, and someone reading the methods would see it gave NADH with a second compound. The point is not pedantry. A result recorded for NADH cannot simply be credited to NAD+, and the human trial on which most marketing leans gave the other form.

Question 12

What would a fair comparison need?

Accepted Answer

It would need what the existing human trial had, plus the arms it lacked. That trial got several things right, being a proof-of-concept, 8-week, randomized, controlled, double-blind trial in which neither patients nor staff knew who was in the active arm. A fair comparison against glutathione, semaglutide or SS-31 would add a second active arm, use one named form of NAD+ rather than a pair, and measure an outcome a reader cares about. A registered study titled Nicotinamide Adenine Dinucleotide Responses to a Nutritional Supplement shows the more common design, which measures a level rather than an outcome. The trial authors themselves wrote that further additional larger controlled trials are needed to confirm these findings, about the single comparison that exists. Until a study of that shape is run, any ranking of NAD+ against another compound is an opinion rather than a result.

NAD+ comparisons and stacks